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1. General introduction and outline of the thesis  
 
The epidemic spreading of obesity that currently affects both developed and 
developing countries is well defined by the term ―globesity‖ (1,2,3). In 2008, 
according to the World Health Organization (WHO), 1.4 billion adults, 20 years 
of age and older, were overweight with an estimated 500 million adults 
worldwide being obese (over 200 million men and nearly 300 million women) 
(2,3,4)
. Noteworthy, the prevalence of obesity has tripled since the 1980s in many 
countries of the WHO European Region with overweight and obesity affecting 
50% of the population in the majority of European countries 
(2,3,4)
. If current 
trends continue, almost 60% of the world's population will be overweight (2.2 
billion) or obese (1.1 billion) by 2030 
(5)
. Obesity is often associated with severe 
and progressive complications, such as cardiovascular events, hypertension, 
dyslipidemia, hyperuricemia, sleep apnoea, cancer, osteoarthritis, depression, 
infertility. Moreover, the lifespan of severely obese individuals is decreased by 
an estimated 5 to 20 years depending on gender, age and race 
(6)
. Indeed, body 
mass index (BMI) is an independent risk factor for premature mortality 
(7)
 and 
for the development of type 2 diabetes mellitus (T2DM) and is also associated 
with the rapid increase of its incidence 
(8)
. It was estimated that for every 1 kg 
increase in body weight, the risk of diabetes grows from 4.5 to 9% 
(9)
. In the 
majority of European countries, overweight and obesity are responsible for about 
80 % of cases of type 2 diabetes 
(4)
. The term "diabesity" expresses the causal 
relationship between the two syndromes.  
Bariatric surgery is considered an effective therapeutic option for obese patients 
to achieve a significant and sustained reduction in body weight with 
improvement or remission of the associated co-morbidities and, in particular, of 
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the metabolic ones 
(10,11,12,13,14,15)
. In addition, bariatric surgery is proven to 
reduce overall and cardiovascular mortality 
(16,17,18)
 and to determine an overall 
improvement of the quality of life 
(19)
. In the last decade, increasing evidence has 
shown that bariatric surgery is able to improve glucose metabolism or even 
reverse T2DM. For these reasons, it is considered an effective tool for the 
treatment of diabesity.  
The present project was designed to assess the impact of bariatric surgery on 
clinically-relevant outcomes and to highlight the pros and cons of this 
therapeutic tool on specific metabolic, cardiovascular and nutritional aspects.  
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2. Overview of bariatric procedures  
2.1 Indications to bariatric Surgery 
According to the recommendations of the National Institutes of Health 
Consensus Conference (1991), obese patients with Body Mass Index (BMI) ≥40 
kg/m
2
 or >35 kg/m
2
 in the presence of co-morbidities, who has failed repeated 
dietary and behavioral approaches and/or drugs for treatment of obesity, are 
candidates for bariatric surgery. These recommendations focusing on BMI as a 
principal determinant of mortality in obese patients has revealed important limits 
(20)
. Indeed, these indications do not take into account the distribution of fat 
(somatic or visceral), a key factor in determining the metabolic syndrome, and 
the different distribution of fat in relation to age, gender and race. 
For this reason, BMI is considered an important benchmark, but not the only one 
to establish the indication for bariatric surgery. 
Moreover, bariatric surgery has revealed to be effective in patients with class 1 
obesity (BMI between 30 and 35 kg/m
2
) and obesity-related comorbidities. To 
date, there is growing evidence on the usefulness of the bariatric approach in 
patients with class I obesity. Indeed, randomized-controlled trials, 
prospective/retrospective studies and meta-analyses on class I obesity patients 
show the effectiveness of bariatric surgery in terms of both weight reduction and 
improvement of comorbidities 
(21,22,23,24,25,26)
.  
On the basis of these data, BMI has to be evaluated together with metabolic, 
functional and psychological parameters for an overall balance between risks 
and benefits. 
Moreover, the choice of the surgical treatment has to take into account the 
presence of absolute and relative contraindications, reversible or irreversible, in 
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the psychological/psychiatric field. In particular, according to current Italian 
guidelines 
(27)
: 
- anxiety disorder and/or depression are considered negative predictors for 
the outcome of bariatric surgery but not an absolute contraindication if 
associated with a psychiatric therapy; 
- active bipolar disorder, schizophrenia, psychosis, alcohol addiction and 
bulimia nervosa are absolute contraindications; 
- patients with Binge Eating Disorder or Night Eating Syndrome has 
indication for bariatric surgery only after multidisciplinary evaluation 
and psychotherapeutic treatment. 
 
2.2  Surgical Techniques 
Bariatric surgical procedures (Figure 1) can be classified on the basis of their 
mechanism of action in: restrictive, malabsorptive and restrictive- 
malabsorptive. 
Restrictive procedures 
Restrictive procedures promote weight loss by reducing gastric capacity through 
the creation of a small gastric pouch whose wall mechanoreceptors are 
stimulated by the food, thus activating the hypothalamic centers deputies to 
decreased appetite 
(28)
. The maintenance of the sense of satiety depends on the 
degree of gastric restriction and, in turn, on the gastric wall stretching. Correct 
eating behavior is fundamental not only to achieve the sense of satiety, but also 
for the maintenance of the restriction volume and therefore of weight loss.  
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 Adjustable Gastric Band  
Adjustable Gastric Banding (AGB) consists of the placement of an inflatable 
silicone band around the upper portion of the stomach, creating a small proximal 
gastric pouch (about 30 ml) above the band. This procedure is minimally 
invasive and has the advantage to be reversible because of the ability of the 
prosthesis to tighten or widen the passage between the proximal and distal 
stomach by the insufflation of the band. 
 Sleeve Gastrectomy  
SG is a bariatric technique consisting of subtotal vertical gastrectomy with 
preservation of the pylorus, including longitudinal resection of fundus, corpus 
and antrum, to create a tubular duct along the lesser curvature. Resection 
comprises approximately 80% of the stomach and the remnant gastric has a 
capacity > 100 mL. 
Sleeve Gastrectomy (SG) or vertical gastrectomy consists of a subtotal vertical 
gastrectomy along the greater curvature with longitudinal resection of gastric 
fundus, corpus and antrum. It creates a ―sleeve‖ along the lesser curvature with 
preservation of the pylorus. Resection comprises approximately 80% of the 
stomach and the remnant gastric has a capacity > 100 mL.  
This procedure is not reversible. The mechanism of action does not involve only 
volume restriction but it encompasses a series of more complex neural/hormone 
mechanisms .  
Unlike other restrictive techniques such as AGB, SG accelerates gastric 
emptying 
(29)
 and intestinal transit 
(30)
. It seems that the rapid transit may trigger 
hormonal changes (in GLP-1, PYY, Ghrelin) that may contribute to weight loss 
(31)
.  
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Malabsorptive procedures 
Malabsorptive procedures enhance weight loss by altering the structure of the 
digestive tract, allowing food to bypass portions of the small intestine. The only 
strictly malabsorptive weight loss surgery is biliopancreatic diversion. 
 Biliopancreatic diversion 
Biliopancreatic diversion (BPD) was originally described by Scopinaro in 1979 
as an alternative to jejunoileal bypass for severely obese patients. The BPD 
procedure consists of: a) partial distal gastrectomy in which the duodenal stump 
is closed (or bypass of the distal part of the stomach); b) transection of the small 
bowel approximately halfway between the ligament of Treitz and the ileocecal 
valve; c) Roux-en-Y gastroenterostomy from the gastric pouch to the distal 
bowel loop creating an alimentary limb; d) a biliopancreatic limb anastomosed 
with the alimentary limb 50 cm before the ileocecal valve forming a common 
channel 
(32)
. The addition of the duodenal switch (DS), in which a vertical sleeve 
gastrectomy is combined with a duodenoenterostomy, was termed the ―second 
generation BPD‖. DS involves preservation of the lesser curvature, antrum, 
pylorus, and first part of the duodenum along with lengthening of common 
channel lengths from 50 cm to 100 cm or more. These modifications were 
created to control for complications associated with Scopinaro's original 
description including marginal ulceration, vomiting, diarrhea, dumping 
syndrome, and micronutrient deficiencies. Indeed, after BPD the food does not 
mix with the bile and pancreatic enzymes until very far down the small intestine. 
This results in a significant decrease in the absorption of calories and nutrients 
(particularly protein and fat) as well as nutrients and vitamins dependent on fat 
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for absorption (fat soluble vitamins and nutrients). For all this reasons, BPD/DS 
is one of the most complex and highest risk bariatric surgeries utilized today. 
Restrictive-malabsorptive procedures 
Restrictive-malabsorptive procedures associate the bypass of small bowel to the 
reduction of gastric volume in order to maximize their effects on body weight 
while reducing the complications intrinsic to purely malabsorptive approach.  
 Roux-en-Y Gastric Bypass  
Roux-en-Y Gastric Bypass (RYGB) consists of the creation of a small gastric 
pouch (15–30 mL) on the lesser gastric curvature (33,34) which is completely 
divided from the gastric remnant and then anastomosed to the jejunum. Bowel 
continuity is restored by an entero-entero anastomosis between the excluded 
biliopancreatic limb and the alimentary limb. This anastomosis is usually 
performed 100–150 cm distal to the gastro-jejunostomy. The RYGB works by 
several mechanisms. First, similarly to most bariatric procedures, the newly 
created stomach pouch is considerably smaller and facilitates significantly 
smaller meals, which translates into less calories consumed. Additionally, 
because there is less digestion of food by the smaller stomach pouch, and there is 
a segment of small intestine that would normally absorb calories as well as 
nutrients that no longer has food going through it, there is less absorption of 
calories and nutrients. 
Most importantly, the rerouting of the food stream produces changes in gut 
hormones that promote satiety, suppress hunger, and reverse one of the primary 
mechanisms by which obesity induces type 2 diabetes 
(35)
. 
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 Single anastomosis (mini-) gastric bypass  
Laparoscopic single anastomosis (mini-) gastric bypass (SAGB) creates a small 
gastric pouch of approximately 60 ml excluded from the rest of the stomach and 
connected to the small bowel by end-to-side anastomosis at a distance from the 
duodenum, not completely standardized, which normally corresponds to about 
200 cm 
(36)
. This is a key element, since in this way the distance of the 
anastomosis can vary from 600 to 200 cm, giving the intervention a 
malabsorptive connotation almost unpredictable 
(27)
. 
 
Figure 1. Most common bariatric procedures. 
 
2.3 Epidemiology of bariatric procedures 
 
Between 150,000–200,000 bariatric procedures are performed annually in the 
U.S., and approximately 250,000 are performed outside the U.S. 
(37)
. SG and 
RYGB are the most performed bariatric procedures. In particular, the frequency 
of use of the different procedures is: SG 49%, RYGB 43%, AGB 6%, and 
BPD+DS 2% 
(38)
. SG has only recently replaced RYGB as the most common 
procedure worldwide, while AGB has steadily declined in usage over the past 5–
8 years 
(38)
. 
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3. Impact of bariatric surgery on clinical outcomes: literature data 
 
3.1 Effect on body weight 
According to the current literature, bariatric surgery is the most effective weight-
loss therapeutic option in terms of both magnitude of weight loss and durability. 
Weight loss is usually expressed as either percent weight loss ([weight loss in 
kg/initial weight in kg] X 100%) or percent excess weight loss (EWL) ([initial 
weight in kg - final weight in kg]/[initial weight - ideal body weight in kg] X 
100%) 
(39)
. Buchwald et al. in a meta-analysis on 136 studies (on 22 094 
patients) showed a mean percentage of EWL of 61.2% (58.1%-64.4%) for all 
patients; 47.5% (40.7%-54.2%) for patients who underwent AGB; 61.6% 
(56.7%-66.5%) for RYGB; 68.2% (61.5%-74.8%) for gastroplasty; and 70.1% 
(66.3%-73.9%) for BPD 
(40)
. As to SG, the average EWL is 50–55%, covering 
an intermediate position 
(41)
. Data from Swedish Obese Subjects (SOS) study 
(12)
, 
one of the largest and longest prospective studies, showed at 20 years follow-up 
a mean percent weight loss of 26% for gastric bypass and 13% for gastric 
banding compared with 1% for control subjects. By contrast, long-term medical 
(nonsurgical) weight loss rarely exceeds 5% 
(42)
. Moreover, also the expected 
percentage regaining weight back to baseline changes on the basis of the 
procedure performed: 18% for AGB, 5% for SG, and 2% for RYGB 
(43)
. 
 
3.2 Remission of type 2 diabetes 
Pories et al. in 1987 
(44)
 published the interesting observation that almost all 
(99%) diabetic patients with severe obesity undergoing gastric bypass, achieve 
normalization of blood glucose levels. This effect occurs very early (few days 
after surgery). Subsequently, it was shown that both malabsorptive and 
restrictive procedures were able to improve glycemic control. Data from a meta-
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analysis on 621 
(45)
 studies for a total of 135,246 patients, showed that the effect 
of bariatric surgery on the improvement/remission of diabetes is very different 
depending on the surgical technique performed: 94% in patients undergoing 
BPD, 81.6% with RYGB and 55% with AGB. The SOS study reported a T2DM 
remission rate of 72% at 2 years and 36% at 10 years compared with 21% and 
13%, in non operated, control subjects (P<0.001) 
(10)
. The same study reported a 
50% reduction in the chronic diabetic complications after surgery 
(46)
. At 15 
years follow-up, the cumulative incidence of microvascular complications was 
41.8 per 1000 person-years (95% CI, 35.3-49.5) for control patients and 20.6 per 
1000 person-years (95% CI, 17.0-24.9) in the surgery group (hazard ratio [HR], 
0.44; 95% CI, 0.34-0.56; P < .001). Macrovascular complications were observed 
in 44.2 per 1000 person-years (95% CI, 37.5-52.1) in control patients and 31.7 
per 1000 person-years (95% CI, 27.0-37.2) for the surgical group (HR, 0.68; 
95% CI, 0.54-0.85; P = .001) (46). With regard to randomized-controlled trials 
(RCTs), a recent meta-analysis of RCTs comparing bariatric surgery with 
medical treatment of T2DM 
(43)
 has shown the net superiority of bariatric 
surgery despite some variability in study design and patients characteristics 
among studies. Indeed, all but 1 study 
(47)
,showed that surgery was superior to 
medical treatment with respect to the primary end point (P<0.05 for all) (Figure 
2). In particular, HbA1c decreased by 2%–3.5% with surgery and 1–1.5%, with 
medical treatment. 
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Figure 2. Panel A: Characteristic of RCTs – Panel B: Forest plot of mean differences (MDs) of %HbA1c serum levels after bariatric/metabolic 
surgery compared with medical/lifestyle treatments in published RCTs 
(43)
. 
 
 
A 
B 
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Although physiological mechanisms behind T2DM remission are not completely 
understood, some evidence supports a key role of the gut hormones in the 
improvement of glucose homeostasis after bariatric surgery. Ghrelin, peptide YY, 
glucose-dependent insulinotropic peptide (GIP), and glucagon-like peptide 1 
(GLP-1) are the gut hormones of particular interest. GLP-1 and GIP, known as 
incretins, are gastrointestinal hormones that stimulate postprandial β-cell insulin 
release, inhibit glucagon, slow gastric empting, and promote weight loss. GLP-1 
is co-secreted with peptide YY by enteroendocrine L cells of the ileum and colon 
in response to a carbohydrate load. RYGB patients demonstrate an immediate 3- 
to 5-fold increase in postprandial GLP-1 and peptide YY levels postoperatively, 
which precedes significant weight loss and is independent of caloric restriction 
(48)
. Restored GLP-1 levels may contribute to the recovery of early phase insulin 
secretion in response to oral carbohydrates. With regard to Ghrelin response after 
RYGB, the data of the literature are quite heterogeneous and therefore its 
contribution to the reduced appetite and improved glucose homeostasis remains 
unclear 
(49)
. 
Two hypotheses have been proposed to explain the changes in gut hormones 
levels after bariatric surgery 
(50). The ―hindgut hypothesis‖ suggests that the quick 
transit of nutrients to the distal bowel improves glucose metabolism by 
stimulating secretion of GLP-1 and other appetite-suppressing gut peptides. The 
―foregut hypothesis‖ proposes that the exclusion of the duodenum and proximal 
jejunum from the transit of nutrients may prevent the secretion of yet unknown 
factor(s) that promote(s) insulin resistance and type 2 diabetes mellitus.  
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Further studies are needed to clarify the exact role of gut hormones in T2DM 
remission after bariatric surgery and to highlight any procedure-specific effect on 
their secretion pattern. 
 
3.3 Decrease in cardiovascular risk and mortality 
The overall impact of bariatric surgery on cardiovascular (CV) risk factors is well 
documented in a recent systematic review 
(51)
. Across 19,543 surgical subjects 
with a mean follow-up period of 57.8 months, the average EWL for all procedures 
was 54% and hypertension remitted or resolved in 63% of affected subjects, 
dyslipidemia in 65%, and diabetes mellitus in 73%. The favorable effect of 
bariatric surgery on CV risk factors translates into reduced CV mortality, as 
shown by Vest et al. 
(52)
 (Table 1). Despite the absence of RCTs, a series of large 
studies 
(53,16,54) 
comparing post-bariatric patients with matched nonsurgical 
controls, consistently showed a 40%-60% higher survival in surgical patients 
versus nonsurgical control subjects. At 14.7 year follow-up of the SOS study 
(12)
. 
Cardiovascular mortality in the surgical group was significantly lower than that of 
control subjects (adjusted hazard ratio, 0.47; 95% CI, 0.29– 0.76; P=0.002) 
despite the greater prevalence of smoking and higher baseline body weight and 
blood pressure in the surgical cohort. This finding has been confirmed and 
extended in a recent meta-analysis 
(55)
 of 14 studies: compared to nonsurgical 
controls, there was more than 50% reduction in mortality among bariatric patients 
(OR 0.48 95% CI 0.35-0.64, I
2
=86%). In pooled analysis of 4 studies with 
adjusted data, bariatric surgery was associated with a significantly reduced risk of 
composite cardiovascular adverse events (OR 0.54 95% CI 0.41-0.70, I
2
=58%). 
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Table 1. Major Studies of Bariatric Surgery With Cardiovascular Event or 
Mortality End Points 
(52)
. 
Authors, Year Follow-up Period Outcomes 
MacDonald et 
al.,1997 
(56)
 
9 y (mean) for 
subjects, 6.2 y for 
control subjects 
9% Mortality in subjects (including perioperative) vs 
28% in control subjects (P<0.0003); annualized 
mortality rate of 1.0% in subjects vs 4.5% in control 
subjects 
Christou et al., 
2004 
(57) 
 
5y 
0.68% Mortality in surgical group (including 0.4% 
perioperative mortality) vs 6.17% for control subjects 
(RR, 0.11; 95% CI, 0.04–0.27) 
Flum and 
Dellinger, 2004 
(53)
 
Median, 4.4 y; 
maximum, 15.5 y 
At 15 y, 11.8% mortality in subjects vs 16.3% in control 
subjects; after propensity matching, odds of survival at 5 
y, 59% higher in surgical group (OR, 1.59; 95% CI, 
1.49–1.72) 
Sampalis et al., 
2006 
(58)
 
5y 
Decreased incidences of new pulmonary edema (RR, 
0.42; 95% CI, 0.18–0.96), angina (RR, 0.53; 95% CI, 
0.40–0.70), coronary artery bypass grafting (RR, 0.28; 
95% CI, 0.14–0.61), and coronary angioplasty (RR, 
0.36; 95% CI, 0.19–0.66) 
Livingston et 
al., 2006 
(59)
 
Maximum, 2 y 
30-d cardiac arrest rate, 1.6%; 30-d myocardial 
infarction rate, 0.5%; overall 30-d mortality, 1.4%; and 
2-y mortality, 3.1% 
Adams et al., 
2007 
(54)
 
Mean, 7.1 y 
lower in surgical group (adjusted HR, 0.60; 95% CI, 
0.45–0.67; P<0.001); lower surgical mortality for all 
diseases combined (52%; P<0.001), CAD (59%; 
P=0.006), diabetes mellitus (92%; P=0.005), and cancer 
(60%; P=0.001) 
Torquati et al., 
2007 
(60)
 
5 y 1% for CV event rate at 5 y 
Sowemimo et 
al., 2007 
(61)
 
9 y 
2.9% Mortality in subjects vs 14.3% in control subjects; 
adjusted mortality, 82% lower in surgical subjects (HR, 
0.18; 95% CI, 0.09–0.35; P<0.0001) 
Busetto et al., 
2007 
(16)
 
5 y 
Survival was 60% higher in surgical group (P=0.0004); 
on multivariate Cox analysis, adjusted mortality risk was 
0.36 (95% CI, 0.16–0.80) in the surgical group 
Peeters et al., 
2007 
(62)
 
Median, 4 y for 
surgical subjects; 
mean, 12 mo for 
control subjects 
Surgical patients had a 72% lower risk of mortality, 
adjusted for sex/age/BMI, than control subjects (HR, 
0.28; 95% CI, 0.10–0.85 
Maciejewski et 
al., 2011 
(63)
 
Mean, 6.7 y 
2- and 6-y crude mortality significantly lower 
for surgical patients (2.2% vs 4.6% [P<0.001] and 6.8% 
vs 15.3% [P<0.001], respectively); significance of 
mortality benefit lost with propensity matching of 1694 
patients (HR 0.83; 95% CI, 0.61–1.14) 
Adams et al., 
2012 
(64)
 
6 y 
2.9% Mortality (12 of 418) in the surgical 
cohort vs 3.3% and 0.9% mortality in control groups 1 
and 2, respectively 
Sjöström et al., 
2012 
(12)
 
Median, 14.7 y 
Lower CV mortality rate in surgery group 
(adjusted HR, 0.47; 95% CI, 0.29–0.76; P=0.002); first-
time CV events also lower in surgical group (adjusted 
HR, 0.67; 95% CI, 0.54–0.83; P<0.001) 
Romeo et al., 
2012 
(65)
 
Mean, 13.3 y 
Adjusted HR for myocardial infarction, 0.56 
(95% CI, 0.34–0.93; P=0.025); adjusted HR for first-
time CV event, 0.53 (95% CI, 0.35–0.79; P=0.002) 
BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; CV, cardiovascular; 
HR, hazard ratio; OR, odds ratio; RR, relative risk. 
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Moreover, bariatric surgery resulted to be associated with significant reduction in 
specific endpoints, such as myocardial infarction (OR 0.46 95% CI 0.30-0.69, 
I
2
=79%, 4 studies) and stroke (OR 0.49 95% CI 0.32-0.75, I
2
=59%, 4 studies). 
 
3.4 Overall mortality and cancer outcomes 
A further issue is whether bariatric surgery could improve other important long-
term outcomes , such as overall mortality and cancer. To date, the findings in the 
published literature are inconsistent. Indeed, some evidence suggested potential 
benefits in the reduction of mortality and cancer 
(16,11)
 and some not 
(64,66)
. A 
recent meta-analysis suggests that, compared to nonsurgical treatment, bariatric 
surgery could reduce all-cause mortality and the risk of cancer in obese patients. 
In particular, the analysis of 19 studies on overall mortality showed lower all-
cause mortality in bariatric patients (1274/28,528 [4.5%] vs. 14,574/171,852 
[8.5%], OR 0.38, 95%CI 0.29 to 0.50, I
2
=91%) and the analysis of 6 studies on 
cancer outcomes showed statistically lower incidence of cancer in the bariatric 
group (OR 0.65, 95%CI 0.46 to 0.91, I
2
=86%). 
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4. Personal research areas 
4.1 Bariatric surgery and cardiometabolic effects 
4.1.1 Glucose homeostasis and lipid metabolism  
As reported above, RYGB and SG are the most widely performed bariatric 
procedures with a proven good clinical efficacy in obese patients with T2DM 
(37,43)
. Previous studies have examined the effects of the two procedures with 
regard to diabetes remission, but limited information is available on the 
contribution of intervention-specific changes in gastrointestinal (GI) hormonal 
pattern to the remission of diabetes. To this end, we performed a prospective 
study 
(67)
 to compare the changes in insulin sensitivity, insulin secretion, and 
postmeal GI hormone levels in obese patients with T2DM 1-year after SG or 
RYGB, in order to evaluate the hormonal and metabolic mechanisms involved in 
weight loss and remission of T2DM. 
The study group included 33 obese patients with T2DM (M/F: 14/19; mean age: 
46±9 years, BMI: 44±8 kg/m
2
), who were on a waiting list for bariatric surgery. In 
total, 14 subjects underwent RYGB and 19 subjects underwent SG. Antidiabetic 
treatment was oral hypoglycemic agents (OAD) in 24 patients, combined OAD 
plus bedtime insulin in 5 patients and diet alone in 4 patients. None was on 
multiple insulin injection regimen. Fourteen patients (74%) in SG and 9 (64%) in 
RYGB were on antihypertensive drugs; 5 patients (36%) in the RYBG group and 
3 patients (16%) in the VSG group were on hypolipidemic treatment. Before and 
one year after the bariatric procedure, anthropometric, clinical and routine 
laboratory parameters were collected together with data on medication use. On 
both occasions, in the morning after a 12-h overnight fast, a standard glucose 
tolerance test (OGTT, 75g of glucose) was performed in order to evaluate insulin 
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secretion and insulin sensitivity. The day after, a liquid mixed-meal test (MMT) 
(304 kcal, containing 41 g carbohydrate, 13 g protein, and 9 g fat) was performed 
to evaluate GI hormonal response.  
During MMT, blood samples were drawn at times 0, 30, 60, 90, 120, and 180 min 
for the measurement of glucose, insulin, active GLP-1 and total GIP 
concentrations at 0, 60, 120, and 180 min for the measurement of total ghrelin.  
 Insulin sensitivity and insulin secretion indexes were derived from glucose, 
insulin, and C-peptide values measured every 30min for 3h during the OGTT. 
Insulin sensitivity was assessed as the oral glucose insulin sensitivity (OGIS) 
(68)
. 
Insulin secretion as total amount of the hormone released by the beta cells (ISR) 
was calculated from C-peptide with the deconvolution method 
(69)
. Beta-cell 
function, which reflects the release of the hormone normalized to the glycemic 
stimulus, was assessed as ―early‖ (IGI30= ratio between incremental C-peptide 
concentration and incremental glucose concentration at 30min) and ―total‖ 
insulinogenic index (IGItotal= AUCCpeptide/AUCGlucose). The interplay 
between insulin sensitivity and secretion, that describes the beta-cell adaptive 
response to changes of insulin sensitivity, was determined by the product 
OGIS×AUCCpeptide (adaptation index, AI) 
(70)
.  
Partial T2DM remission was defined as HbA1c <6.5% (47.5mmol/mol) and 
fasting glucose <126 mg/dl in the absence of antidiabetic medications. Complete 
remission was defined as HbA1c <6% (42.1mmol/mol) and fasting glucose <100 
mg/dl in the absence of antidiabetic medications. 
Main clinical and metabolic characteristics of participants before and one year 
after surgery are reported in Table 2. Age, BMI, duration of diabetes, glucose 
control, and lipid profile at baseline were similar between RYGB and SG groups. 
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At one-year, weight loss both expressed as percent change in BMI and expressed 
as EWL% was similar after the two interventions (p=0.546 and p=0.146 
respectively). Glycemic control improved similarly in the two groups with a mean 
HbA1c reduction of 2-2.5% (18–26 mmol/mol) from baseline values. Fasting 
triglycerides levels fell markedly after both procedures; plasma total and LDL-
cholesterol decreased after RYGB whereas they remained substantially unchanged 
after SG (Table 2).  
Table 2. Clinical and metabolic characteristics of participants before and one year 
after surgery. 
 
The remission of diabetes (partial plus total) was achieved in 14 SG patients 
(74%) and in 12 RYGB patients (86%) (p=0.28). Insulin secretion and insulin 
sensitivity (OGTT) Total insulin secretion (ISR) did not change, while beta-cell 
function improved to a similar extent one year after surgery (Table 3). Insulin 
sensitivity (OGIS) was similar in the two groups, preoperatively and markedly 
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improved after either procedures (p <0.001 for both). Adaptation index (AI) 
increased to a similar extent after surgery with no difference between RYGB and 
SG.  
Table 3. Insulin sensitivity and insulin secretion, and glucose and hormonal 
response to MMT before and one year after surgery. 
 
Glucose and hormone profile (MMT) IAUCGlucose decreased while IAUCInsulin 
increased after surgery with no difference between interventions (Figure 3). 
Meal-stimulated GLP-1 concentrations were flat in all patients preoperatively. 
Following RYGB, both GLP-1 peak and IAUC increased markedly (p = 0.001), 
while after SG, the release of GLP-1, although increased compared to presurgery, 
was much lower than in patients operated of RYGB (p = 0.0001). Meal GIP 
response after surgery decreased by 50 % (p = 0.001 after RYGB and p = 0.05 
after SG) with no difference between interventions. Neither fasting nor nadir 
ghrelin during MMT changed after RYGB; in contrast, a marked suppression in 
both variables occurred after SG with a significant difference between the 2 
intervention (p = 0.013 for fasting ghrelin and p = 0.035 for nadir ghrelin 
concentrations) (Figure 3 and Table 3).  
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Figure 3. Glucose, insulin, GLP-1, GIP, and ghrelin response to a mixed meal in 
RYGB and SG subjects before (continuous line) and one year (dotted line) after 
surgery.  
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The increase in insulin sensitivity and beta-cell function was correlated with 
weight loss (R = 0.425, p = 0.014 and R = 0.461, p = 0.035, respectively) (Figure 
4) while no association was found with GI hormone concentrations. 
 
Figure 4. Correletion between excess weight loss (EWL) and changes of insulin 
sensitivity (OGIS) in SG (circle) and RYGB (square) subjects.  
 
In this study, we found that RYGB and SG resulted to be equally effective in 
terms of weight loss and improvement of glycemic control, with a similar rate of 
T2DM remission at 1 year (76 % after VSG and 86 % after RYGB); on the other 
hand, the two procedures are characterized by a different GI hormonal pattern.  
This finding leads us to hypothesize that the changes in gut hormones are not the 
main determinant of the metabolic improvement, at least several months after 
surgery. However, since our evaluations were performed one year after surgery 
we cannot rule out that the changes in GI hormonal profile may have contributed 
to diabetes remission early after surgery. This hypothesis is in line with a recently 
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published commentary, which underlined that the mechanisms behind the 
remission of diabetes after SG or RYGB may differ in relation to the time at 
which they are studied. Early after surgery, the improvement of glycemic control 
is due to increased hepatic insulin sensitivity and to the improved beta-cell 
function consequent to the exaggerated postprandial GLP-1 secretion. Later on, 
with progressive weight loss the improvement in peripheral insulin sensitivity 
becomes the prevalent mechanism 
(71)
.  
Besides glucose metabolism, there is clinical evidence that bariatric surgery exerts 
long-term favorable effects on fasting lipid levels with reduction of triglycerides 
and LDL cholesterol and increase in HDL cholesterol concentrations 
(72)
. 
Moreover, although a number of studies have addressed incretin regulation of 
glucose homeostasis 
(73,74)
, much less is known about the relationship between 
incretin hormones and lipid metabolism and the effects of bariatric surgery on 
impairment of postprandial lipid profile, which is considered as an independent 
cardiovascular risk factor 
(75)
. Accordingly, we performed a study 
(76)
 with the aim 
to evaluate the short-term (2 weeks) effects of bariatric surgery on fasting and 
postprandial lipid metabolism in obese T2DM patients and to establish whether 
changes in lipid profile are related to active GLP-1 changes. 
Twenty-five obese T2DM2 patients (12 men and 13 women) were studied. Fifteen 
patients underwent SG, and ten underwent RYGB. All participants were studied 
before and 2 weeks after surgery. In both occasions, anthropometric, clinical, and 
laboratory parameters were collected together with data on medication use. In 
addition, plasma levels of glucose, insulin, lipids, and active GLP-1 were 
evaluated at fasting and after a standard MMT (composition reported above). 
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The clinical and metabolic characteristics of participants before and after surgery 
are given in Table 4. At week 2 after surgery, there was a significant reduction in 
body weight, fasting plasma glucose, and insulin as well as a marked reduction in 
insulin resistance, as evidenced by a 50% decrease in HOMA-IR. Glucose 
response to the MMT was significantly reduced compared to pre-intervention, 
while insulin response increased without reaching the statistical significance. The 
response of active GLP-1 to the MMT increased significantly after surgery.  
Table 4. Clinical and metabolic characteristics of the patients before and two 
weeks after surgery. 
 
 
Data are means±SD or median and interquartile range (25, 75) BMI body mass 
index, IAUC incremental area under curve, HOMA-IR homeostasis model 
assessment of insulin resistance  
 
The changes in lipid concentrations after surgery are reported in Figure 5. After 
surgery, there was a significant reduction in fasting plasma TG (182 mg/dl (110, 
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231) vs. 130 mg/dl (104, 165), p <0.05), total cholesterol (170±41 vs.148±29 
mg/dl, p <0.005), LDL cholesterol (119±30 vs. 100±28 mg/dl, p <0.05), and HDL 
cholesterol (37±9 vs. 30±10 mg/dl, p <0.001). 
Figure 5. Plasma concentration and IAUC of plasma triglycerides (a), plasma 
total cholesterol (b), and plasma HDL cholesterol (c) after mixed meal before 
(black diamond) and 2 weeks after (light grey square) bariatric surgery. Data are 
means±SE. * p <0.001 vs. 2 weeks; **p<0.05 vs. 2 weeks. 
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Post-MMT plasma TG, total cholesterol, and HDL cholesterol were significantly 
lower compared to pre-intervention. IAUC of plasma TG decreased markedly by 
60 % (4,050 mg/dl·180 min (2,019, 8,409) vs. 1,635 mg/dl·180 min (390, 
−2,603), p <0.001), while no difference was observed in IAUC of total and HDL 
cholesterol (Figure 5). Analyzing postprandial lipid response according to the type 
of surgery (SG or RYGB), no difference was found between the two procedures. 
In order to confirm and further extend these findings, we performed the same 
experimental evaluations in a subgroup of 19 patients (10 undergoing SG and 9 
RYGB) with a 2-year post-surgery follow-up 
(77)
. 
Postprandial triglycerides markedly decreased whereas HDL cholesterol increased 
after both interventions (Figure 6). Conversely, postprandial LDL cholesterol 
levels were significantly lower after RYGB compared to SG (p<0.05). No 
significant difference was found in the IAUC of triglycerides, HDL, and LDL 
cholesterol between the two interventions (Figure 6). GLP-1 meal response, very 
flat preoperatively, increased after surgery, with a higher increment after RYGB 
(IAUC 1753±271 vs 256±78 pmol/l×180 min, p<0.001). GLP-1 peak was 10±2 
pmol/l after SG and 49±6 pmol/l after RYGB (p=0.001) (Figure 7). The decrease 
of fasting triglycerides was positively correlated with weight loss (R=0.470, 
p=0.049), reduction of HOMA-IR (R=0.679, p=0.001). In the RYGB group, LDL 
cholesterol was inversely related with GLP-1 peak (R=−0.733, p=0.007) adjusted 
for pre-surgery values. The multivariate model, adjusted for age, gender, duration 
of T2DM and HbA1c, showed that GLP-1 peak was the best predictor of LDL 
reduction (β=−0.552, p=0.039) while reduction of HOMA-IR (β=0.574, p=0.014) 
and weight loss (β=0.418, p=0.036) predicted triglycerides improvement.  
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Figure 6. Plasma concentration and IAUC of triglycerides, HDL cholesterol and 
LDL cholesterol after a mixed meal before (continuous line and white bar) and 2 
years (dotted line and gray bar) after sleeve gastrectomy (SG) or gastric bypass 
(RYGB). Data are expressed as means (±SEM). *p<0.05, pre- vs post-surgery 
 
 
 
 
Figure 7. Plasma concentration and IAUC of GLP-1 after a mixed meal before 
(continuous line and white bar) and 2 years (dotted line and gray bar) after sleeve 
gastrectomy (SG) or gastric bypass (RYGB). Data are expressed as means 
(±SEM). *p<0.05 and #p<0.001, pre- vs post-surgery 
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Our data demonstrate that bariatric procedures, namely SG and RYGB, improve 
fasting as well as postprandial lipid profile. This effect occurs within 2 weeks 
after the intervention and persists up to 2 years after. 
The major effect reported is the marked fall in postprandial triglycerides. This 
improvement of triglyceride metabolism was similar with both procedures, both in 
early and in late follow-up. On the other hand, LDL cholesterol levels resulted 
~30 % lower after RYGB than SG 2 years after surgery. This finding is in 
agreement with recent evidence indicating that the type of surgery impacts 
primarily cholesterol metabolism rather than triglycerides. In fact, Benetti et al. 
reported a significant reduction in cholesterol levels after malabsorptive 
procedures (biliopancreatic diversion and biliointestinal bypass) but not after 
purely restrictive procedures (adjustable gastric banding), whereas triglycerides 
decreased similarly with the two types of surgery 
(78)
. Moreover, in line with 
literature data 
(79,80)
, HDL cholesterol decreased a few days after bariatric 
procedures and increased later on during the follow-up. This finding is not 
unexpected because HDL cholesterol tends to decrease in highly dynamic 
conditions (marked reduction of food intake) 
(81)
, such as that immediately after 
bariatric surgery.  
The significant inverse correlation between LDL cholesterol and GLP-1 meal 
response found in our RYGB patients supports the hypothesis that the restoration 
of GLP-1 may contribute to the reduction of plasma cholesterol level. In 
experimental animals, GLP-1 is able to suppress hepatic lipogenesis through 
activation of AMPK pathway 
(82)
 and the genes involved in fatty acid β-oxidation 
(83)
.  
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In conclusion, either RYGB and SG persistently improve glucose metabolism, 
reduce both fasting and postprandial triglycerides, and increase HDL cholesterol. 
LDL cholesterol decreases only after RYGB; this effect—likely mediated by 
surgery-induced GLP-1 restoration—underlines the crucial role of gut in the 
regulation of lipid metabolism. 
 
4.1.2 Glucose variability and oxidative stress  
Bariatric surgery causes a profound rearrangement of the gastro-intestinal 
anatomy that results, among others, in an accelerated gastric emptying 
(84)
. It is 
well established that the rate of gastric emptying is a major determinant of 
postprandial glucose response both in healthy and in diabetic individuals 
(85)
. The 
rapid entry of nutrients into the small intestine causes earlier and higher 
postprandial glycemic peaks followed by lower glucose nadirs, sometimes 
triggering frank hypoglycemic symptoms, as increasingly reported in recent 
studies 
(86,87,88)
. These findings raise the issue as to whether and to which extent 
glucose homeostasis is normalized in diabetic patients undergoing bariatric 
surgery, and prompt for a more accurate assessment of glucose status in the 
postoperative follow-up. Among measures of glucose control, glycemic variability 
(GV), i.e. blood glucose oscillations throughout the day, is gaining increasing 
attention since high GV may be involved in the pathogenesis of diabetic vascular 
complications and mortality risk 
(89,90,91,92)
. In the present study, we performed 
continuous glucose monitoring (CGM) on an ambulatory basis in patients who 
achieved diabetes remission after bariatric surgery in order to evaluate the pattern 
of glucose fluctuation under condition of real life. Since increased glucose 
variability activates oxidative stress 
(93)
, we also measured 24-h urinary excretion 
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of free 8-isoprostaglandin F2α (8-isoPGF2α), a well-recognized marker of 
oxidative stress. 
The study groups included 22 patients (M/F:10/12; mean age: 50 ± 9 years, body 
mass index: 31 ± 6 kg/m
2
) who were in remission of T2DM (T2DM remitters) 
after bariatric surgery since at least 1 year. Ten patients (45%) achieved complete 
remission (fasting plasma glucose <100 mg/dl, HbA1c <6% and no antidiabetic 
medication use) while 12 patients (55%) achieved partial remission (fasting 
plasma glucose between 100 and 126 mg/dl, HbA1C between 6 and 6.5% and no 
antidiabetic medication use). Eleven subjects had undergone RYGB and eleven 
SG. Twenty-two age-, sex- and BMI- matched subjects (M/F: 10/12; mean age: 52 
± 9 years, BMI: 32 ± 6 kg/m
2
) recruited from the obesity outpatient clinic or the 
staff of Federico II University Hospital were enrolled as control. None of them 
had signs of liver, kidney or cardiac disease. 
In all participants, a 75 g OGTT was performed after a 12-h overnight fast with 
sampling at 0’, 30’, 60’, 90’ and 120’ for glucose and insulin measurement. 
Glucose and insulin responses to OGTT were calculated as the area under the 
curve above the baseline values using the trapezoidal method. The day before 
OGTT, they collected 24-h urinary samples for 8-isoPGF2α analysis.  
After an overnight fast, all T2DM remitters and 10 control subjects underwent 
CGM for 7 days with survey of glucose levels in the interstitial fluid every 5 min, 
270 times per day (Dexcom G4 PLATINUM). The application of the 
subcutaneous sensor was performed at the Outpatient Diabetic Clinic and after 
two hours the first calibration was carried out. Each participant was instructed to 
calibrate the CGM device twice daily or whenever alerted by the device. The 
download of glucose monitor data was performed using Dexcom StudioTM. GV 
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was analyzed with regard to the two principal components: amplitude and timing 
(94)
. The amplitude was expressed by standard deviation of blood glucose (SD), 
coefficient of variation (CV), and mean amplitude of glucose excursions (MAGE) 
that was calculated as the arithmetic mean difference between consecutive blood 
glucose peaks and nadirs (between the peaks) when differences were >1 SD of the 
mean glucose value. The timing of GV was expressed as time within target range 
(70-190 mg/dl), time spent in hypoglycemia (blood glucose <70 mg/dl) and time 
spent in hyperglycemia (blood glucose >191mg/dl) 
(89,94)
. 
During CGM, participants filled in a 7-day food record for the assessment of their 
dietary intake. 
Table 5 provides the main clinical and metabolic characteristics of participants. 
The mean postoperative follow-up was 4±2 years (range: 1-7 years). Age, BMI, 
HbA1c and blood pressure were similar in T2DM remitter and in control subjects. 
With regard to lipid profile, T2DM remitters showed higher HDL-cholesterol 
level than control subjects (p<0.05) while no difference was observed in the other 
lipid fractions. 
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Table 5. Clinical, biochemical and metabolic characteristics of study participants. 
 T2DM remitters Controls 
Sex (M/F) 10/12 10/12 
Age (years) 50±9 52±9 
Diabetes duration (years) 4±5 --- 
RYGB/SG 11/11 --- 
BMI (Kg/m2)  
Preoperative BMI (Kg/m2) 
31±6 
43±8 
32±6 
--- 
Time from intervention 4±2 --- 
Fasting blood glucose (mg/dl) 92±17 92±10 
HbA1c (%) 
HbA1c (mmol/mol) 
5.7±0.6 
39±6 
5.2±0.3 
34±4 
Total cholesterol (mg/dl) 187±40 188±44 
HDL-cholesterol (mg/dl) 62±16 43±15* 
LDL-cholesterol (mg/dl) 105±35 110±30 
Triglycerides (mg/dl) 99±43 119±57 
Systolic blood pressure (mmHg) 126±8 121±10 
Diastolic blood pressure (mmHg) 75±6 72±9 
M±SD *p value <0.001 
According to general linear model for repeated measures, glucose response during 
OGTT was significantly higher in T2DM remitter than in control subjects 
(p<0.001). In particular, the difference in plasma glucose level was evident at 30 
and 60 min of the test (p=0.01, for both) (Figure 8). Similarly, insulin response 
was significantly different in the two groups (p<0.001). In particular, plasma 
insulin level was significantly lower in T2DM remitter that in control subjects at 
120 min (p<0.05). Three T2DM remitters showed impaired glucose tolerance (2-h 
blood glucose between 140 and 199 mg/dl) while all control subjects showed 
normal glucose tolerance. 
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Figure 8. Plasma glucose (A) and insulin (B) response to OGTT in T2DM 
remitter and in control subjects. *= p <0.05; §= p <0.001. 
 
Mean interstitial glucose concentration (IG) throughout the 7-day CGM was 
similar in the two groups (Table 6); however, T2DM remitters showed higher 
mean IG peak and lower mean IG nadir than in control subjects (p<0.001 and 
p=0.03). All measures assessing the amplitude of GV, i.e., SD, CV and MAGE, 
were significantly higher in T2DM remitters than in control subjects, (p<0.001 for 
all). The time spent in hyperglycemia (blood glucose >191 mg/dl) as well that 
spent in hypoglycemia (blood glucose <70 mg/dl), expressed as percentage of the 
whole monitoring time, were significantly longer in T2DM remitter compared to 
control subjects (hyperglycemia: 5.0 ± 6.3 vs 0.3 ± 0.5%, p=0.002 and 
hypoglycemia: 16 ± 20 vs. 2.7 ± 2.9, p=0.007). 
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Noteworthy, GV was greater in patients operated of RYGB than in those operated 
of SG, as evidenced by the values of CV (35 ± 5 and 26 ± 4 %, p<0.05) and 
MAGE (136 ± 46 and 99 ± 27 mg/dl, p<0.05) in the RYGB and SG group, 
respectively. 
 
Table 6. Indexes of glucose variability obtained through 7-day CGM and 8-
isoprostaglandin F2α (8-isoPGF2α) in DM2 remitter and in control subjects.  
 T2DM Remitters Controls p value 
Mean IG (mg/dl) 115±23 105±5 0.203 
Mean IG peak (mg/dl) 264±58 178±22 < 0.001 
Mean IG nadir (mg/dl) 55±16 64±6 0.033 
SD (mg/dl) 35±10 21±5 < 0.001 
CV (%) 31±6 20±5 < 0.001 
MAGE (mg/dl) 118±41 61±19 < 0.001 
Time spent at glycemia<70 mg/dl (%) 16±20 2.7±2.9 0.007 
Time spent at glycemia 71-191 mg/dl (%) 79±19 97±3 0.007 
Time spent at glycemia>191 mg/dl (%) 5±6 0.3±0.5 0.002 
8-iso PGF2α (ng/24 h) 1890±1014 1306±459 0.040 
M±SD, IG= interstitial glucose, SD= standard deviation, CV= coefficient of variation, 
MAGE= mean amplitude of glucose excursions  
 
Mean 24-h urinary 8-iso PGF2α excretion was found to be significantly higher in 
T2DM remitters than that in control subjects (1890 ± 1014 and 1306 ± 459 
ng/24h, respectively, p=0.04 ). 
All GV indexes were significantly associated with blood glucose levels at 30 min 
(p<0.05-0.001) and SD and MAGE were associated with blood glucose at 60 min 
during OGTT (p<0.05-0.001). No correlation was found between GV indexes and 
24-h urinary 8-isoPGF2 α. 
Daily caloric intake was similar in the two groups (1550 ± 500 and 1622 ± 434 
Kcal /die). With regard to macronutrient distribution, a similar intake of total 
carbohydrate (48 ± 7 vs. 47 ± 6 %), fat (32 ± 6 vs 34 ± 5 %) and protein (16 ± 3% 
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and 18 ± 4%) was observed in T2DM remitter compared to control subjects. 
Likewise, dietary glycemic index and glycemic load were similar in the two 
groups (59 ± 5 and 117 ± 45 in T2DM remitter and 56 ± 4 and 106 ± 33 in control 
subjects). 
In the present study, we evaluated the daily glucose profile under ―real life‖ 
conditions in patients in T2DM remission after bariatric surgery. Despite all of 
them presented values of fasting blood glucose and HbA1c within the normal 
range, their GV was significantly higher compared with that of age- and BMI-
matched control subjects. Quite strikingly, these patients showed an increased 
oxidative stress, as documented by high urinary excretion of 8-isoPGF2α, 
indicating that high GV may exert a deleterious effect on the vascular system.  
There are consistent data from pathophysiological and clinical studies that high 
GV may be involved in the pathogenesis of diabetic vascular complications via 
activation of inflammatory pathways, increased oxidative stress and endothelial 
dysfunction 
(95,93,96)
. In addition, GV is reported to impact depression, quality of 
life and other mental health outcomes in diabetic individuals 
(90)
. For these 
reasons, GV is now considered a therapeutic target in addition to HbA1c, and 
several studies have focused on the effects of different pharmacologic treatments 
on GV 
(97,98)
. Although our patients fulfilled the agreed criteria of diabetes 
remission, they presented an increased GV. Actually, all measures of amplitude of 
GV were significantly higher than those of control subjects and, more 
importantly, a considerable amount of time (16% of the monitoring period) was 
spent in the hypoglycemic range. Previous studies have reported an increased GV 
in patients undergoing bariatric surgery particularly after RYGB 
(99,100)
. To the 
best of our knowledge, the present study is the first one to demonstrate that in 
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addition to high GV, T2DM remitters present an increased oxidative stress, 
indicating a high risk of vascular damage. The present findings bring us to 
reconsider the concept of remission of diabetes after bariatric surgery and the 
criteria for its definition. It is quite clear that the achievement of normal values of 
fasting blood glucose and HbA1c does not correspond to a true normalization of 
glucose homeostasis, raising the question whether the term "remission" is 
appropriate. Furthermore, it could be appropriate to include measures of GV in the 
assessment of glucose control in patients undergoing bariatric surgery 
(101)
.  
The mechanisms underlying the high GV in our T2DM remitters are not clear. A 
major source of GV is the rapid onset of postprandial hyperglycemia - as a 
consequence of accelerated delivery of dietary carbohydrates- followed by 
reactive hypoglycemia. This mechanism is confirmed by the early and rapid rise 
in plasma glucose observed during the OGTT. Noteworthy, more than 50% of the 
exposure to blood glucose <70 mg/dl occurred in the late postprandial period (>3 
hours after meals). The relation between postprandial hyperglycemia and GV is 
further supported by the significant association between 30 and 60 min OGTT 
blood glucose levels and the amplitude of GV.  
It is known that dietary habits with reference to the consumption of high-index 
glycemic food may contribute to GV both in non-diabetic and diabetic individuals 
(102,103)
. The dietary carbohydrate intake of our patients was in the normal range as 
well as the food glycemic index/glycemic load 
(103)
. Thus, it is conceivable that 
the high GV of our patients is not due to dietary high glycemic load, rather it is a 
likely consequence of the anatomical changes caused by surgery and, in essence, a 
price to pay to achieve long-lasting weight loss. This view is in line with the 
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observation that GV was higher after RYGB than SG, indicating that the more 
profound the gastro-intestinal anatomical changes the higher the GV.  
In conclusion, the remission of T2DM after bariatric surgery is characterized by 
high GV and increased oxidative stress in the face of fasting blood glucose and 
HbA1c within the normal range. This finding calls into question the need of 
critically re-examine the concept of diabetes remission. Long-term studies are 
needed to assess the impact of these glucose abnormalities on chronic diabetic 
complications. In the meanwhile, nutritional and/or pharmacologic strategies 
should be implemented to minimize GV in these patients. 
 
4.1.3 Haemostatic and fibrinolytic parameters 
Evidence so far exposed demonstrates that bariatric surgery is able to impact on 
important metabolic aspects (weight, glucose and lipid homeostasis). On the other 
hand, all these variables have a strong effect on cardiovascular risk and 
coagulation system. In this respect, primary haemostasis (platelet function), 
fibrinolytic variables (tissue plasminogen activator [t-PA], plasminogen activator 
inhibitor-1 [PAI-1]) and secondary haemostatic factors (coagulation proteins; 
natural anticoagulants) are known to play a relevant role in cardiovascular 
pathophysiology 
(104)
. Several studies suggest that obesity is characterised by an 
increased expression of several prothrombotic factors, impaired fibrinolysis and 
platelet hyper-reactivity 
(105)
. Weight loss has been found to (partially) revert both 
metabolic and vascular alterations found in obese subjects 
(106)
. However, little is 
known about the effects of different bariatric surgery techniques on haemostatic 
and fibrinolytic parameters. We have prospectively evaluated changes in major 
haemostatic (fibrinogen, D-dimer, coagulation factors II, VII, VIII, IX, X and von 
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Willebrand factor [vWF], protein C, protein S and antithrombin) and fibrinolytic 
(PAI-1, t-PA, PAI-1/t-PA ratio) variables in obese subjects undergoing single 
anastomosis gastric bypass (SAGB) or SG 
(107)
. Consecutive obese subjects 
referred to the Federico II University Hospital with an indication (according to the 
European Association for the Study of Obesity guidelines) 
(108)
 for bariatric 
surgery were enrolled in this study. Before surgery (T0), information about age, 
gender, cardiovascular risk factors such as obesity, hypertension, impaired fasting 
glucose, hypercholesterolaemia, hypertriglyceridaemia and previous and/or 
current treatments were collected. All clinical and laboratory evaluations were 
repeated in all subjects 60 days (±10 days) after surgery (T1).  
A total of 156 obese patients were enrolled in this study, 77 of whom underwent 
SAGB and 79 who underwent SG. Pre-operatively, the two groups were entirely 
comparable for all major clinical and demographic characteristics and for all 
haemostatic and fibrinolytic variables (Table 7). An increase in at least one of 
haemostatic or fibrinolytic parameters above higher normal levels - suggesting a 
hypercoagulable state - was found in 37 (48.1%) SAGB and 40 (50.6%) SG 
patients (p=0.752). At the 2-month post-operative follow-up (T1), a 21.3% 
reduction in BMI was found in the SAGB group as compared with a 19.1% 
reduction in the SG group (p=0.139).  
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Table 7. Clinical and demographic characteristics of the study population before 
surgery. 
Variable SG 
N=79 
SAGB 
N=77 
p 
Age (years) 37.9±3.1 38.7±3.9 0.186 
Male gender 36(45.6%) 45(58.4%) 0.113 
BMI 45.3±3.1 44.2±4.7 0.114 
PAI-1 antigen 31.7±9.7 33.6±14.5 0.064 
t-PA levels 4.8±1.8 5.4±2.0 0.061 
Fibrinogen 315.8±48.2 314.1±81.9 0.867 
D-Dimer 228.8±232.3 211.9±121.3 0.573 
FII 113.7±17.9 117.5±19.1 0.213 
FVII 124.9±22.2 123.1±22.0 0.613 
FVIII 124.6±20.6 123.5±23.4 0.745 
FIX 133.9±25.5 132.9±24.2 0.814 
FX 97.4±6.8 99.3±7.2 0.094 
vWF 136.1±26.5 130.7±22.7 0.173 
Prot C 116.7±18.3 118.8±15.4 0.441 
Prot S 107.4±18.4 113.1±21.0 0.069 
AT 97.9±6.2 99.7±7.15 0.096 
Hypercholesterolemia  47(59.5%) 38(49.4%) 0.206 
Hypertriglyceridemia 27(34.2%) 25(32.5) 0.866 
Diabetes 39(49.4) 38(49.4) 1.000 
Hypertension 37(46.8%) 44(57.1%) 0.205 
Smoking habit 17(21.5%) 22(28.6%) 0.357 
Obesity 79(100%) 77(100%) 1.000 
 
In parallel, a reduction in haemostatic and fibrinolytic parameters was recorded in 
both the SAGB and SG groups (Figure 9). 
In detail, Δ% changes in the levels of FVII, FVIII, FIX, vWF, fibrinogen, and D-
dimer were significantly greater in the SAGB group than in SG group. In addition, 
SAGB patients showed greater changes in protein C and protein S levels, as 
compared with those undergoing SG. In contrast, no difference was found in 
changes in antithrombin, FII, FX, PAI-1 and t-PA levels between patients 
undergoing the two different surgical procedures. Interestingly, Δ%BMI showed a 
direct correlation with Δ% changes in fibrinogen (r=0.386, p<0.001), FVIII 
(r=0.303, p<0.001), vWF (r=0.211, p=0.008) and PAI-1 (r=0.482, p<0.001), but 
not with any of the other haemostatic parameters. A direct correlation between 
Δ%PAI-1 and Δ%t-PA was also found (r=0.545, p<0.001). Multivariate analysis 
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showed that, after adjusting for major clinical and demographic characteristics 
(including BMI changes), SAGB was consistently associated with greater Δ% 
changes in FVII (β=0.268, p=0.010), protein C (β=0.274, p=0.003) and protein S 
(β=0.297, p<0.001) levels, but not with any of the other variables. 
 
 
Figure 9. Δ% changes of haemostatic and fibrinolytic variables 2 months after 
sleeve gastrectomy (SG) or gastric bypass (SAGB). 
 
Interestingly, at the T1 assessment, 31 subjects (25.9% of SAGB and 13.9% of 
SG patients, p=0.044) had FVII levels below lower normal cut-off values (i.e., a 
FVII deficiency), whereas no deficiency of any other clotting factor was found. In 
these 31 subjects with FVII deficiency, the mean FVII level was 54.5% ± 8.44% 
(normal reference range, 39-69%). As to natural anticoagulant levels, whereas no 
case of antithrombin deficiency was found, protein C deficiency was present in 34 
subjects (32.5% of SAGB patients vs 11.4% of SG patients, p=0.033) and protein 
S deficiency in 39 (37.6% of SAGB patients vs 12.6% of SG patients, p=0.009). 
In the deficient subjects, the mean level of protein C was 57.4% ±4.58 (normal 
reference range, 50-65%) and the mean level of protein S was 63.1% ±3.79 
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(normal reference range, 58-69%). Separate multivariate analyses confirmed that 
GB was associated with an increased risk of deficiency in FVII (odds ratio [OR]: 
3.64; 95% confidence interval [CI]: 1.73-7.64; p=0.001), protein C (OR: 4.319; 
95% CI: 1.33-13.9; p=0.015) and protein S (OR: 5.50; 95% CI: 1.71-17.7; 
p=0.004). 
These results provide evidence about the effects of bariatric surgery on 
haemostatic and fibrinolytic balance. We documented that bariatric surgery is able 
to reduce the hypercoagulable state typical of obese subjects. In detail, we have 
documented a correlation between post-surgical BMI reduction and changes in 
PAI-1, with an approximately 20% reduction in PAI-1, one of the major 
determinants of fibrinolytic potential. Although both SG and SAGB showed a 
clear efficacy in reducing levels of clotting factors, SAGB was associated with a 
greater reduction in FVII, protein C and protein S as compared with those 
following SG. It is interesting to highlight that all three of these factors are 
vitamin K-dependent proteins. Vitamin K is one of the fat-soluble vitamins 
usually absorbed in the proximal small intestine by a saturable energydependent 
process 
(109)
. The risk of malabsorption and vitamin K deficiency after bariatric 
surgery is significant, being reported to occur in 20% of patients after 
malabsorpive procedures 
(110)
. Indeed, most of the malabsorptive bariatric 
procedures (such as SAGB) involve surgical exclusion of a significant portion of 
bowel, usually including the proximal small intestine, which is one of the major 
sites of vitamin K absorption. A lack of vitamin K can be associated with 
deficiencies in vitamin K-dependent clotting factors 
(111)
. Although vitamin K-
deficiency related changes in clotting factors have been thought to increase the 
risk of bleeding in patients who undergo bariatric surgery 
(112)
, data derived from 
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studies on major inherited bleeding disorders (haemophilia A and B, FVII 
deficiency) 
(113,114)
 clearly indicate that mild deficiencies (clotting factor levels 
~40%) in FVII, FVIII and FIX are not associated with an increased risk of 
bleeding. Moving to natural anticoagulants the situation is totally different. 
Antithrombin, protein C and protein S are major compounds of the physiological 
anticoagulant system and their deficiencies are known to be severe risk factors for 
venous thromboembolism 
(115)
. Indeed, some recent data clearly demonstrated that 
even a mild deficiency (factor levels 70-80%) of antithrombin, protein C or 
protein S is associated with an increased risk of thrombosis 
(116,117)
. 
In the present study we have found a deficiency of protein C and protein S in 
21.8% and 25% of patients, respectively. In contrast, no alterations in 
antithrombin levels were found. This is in line with the hypothesis of vitamin K 
deficiency-related alterations, since protein C and protein S are synthesized 
through vitamin K-dependent mechanisms, while the production of antithrombin 
is totally independent of this compound.  
In conclusion, we found that bariatric surgery is able to revert the hypercoagulable 
state usually reported in obese patients; however, in some cases, an acquired 
natural anticoagulant deficiency may occur and this could be associated with an 
increased risk of thrombosis 
(118)
. Thus, changes in vitamin status and in 
haemostatic variables should be strictly monitored after bariatric surgery, 
particularly when malabsorptive procedures are used. 
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4.1.4. Surrogate markers of atherosclerosis 
Obesity can exert direct negative effects on the atherosclerotic process, as well as 
on endothelial function 
(119,120)
 which are established substrates for cardiovascular 
disease and strong predictors of future cardiovascular events 
(121,122)
. 
Carotid intima-media thickness (IMT), flow-mediated dilation (FMD) and nitrate-
mediated dilation (NMD) are considered surrogate markers of subclinical 
atherosclerosis 
(123,124)
. They are widely recognized as independent predictors of 
CV events 
(125,126,127,128)
, thus providing important prognostic data beyond 
traditional CV risk factors.  
Whereas several studies confirmed a significantly increased IMT and impaired 
FMD and NMD in obese subjects 
(119,120)
, few data are available on the effects of 
bariatric surgery on these markers of CV risk. Thus, we performed a systematic 
review and meta-analysis of studies evaluating changes in IMT, FMD and NMD 
in obese patients undergoing bariatric surgery 
(129)
. 
A total of 10 articles (314 obese patients) were included in the analysis, 6 studies 
with data on IMT (7 data-sets on 206 patients), 8 studies on FMD (9 data-sets on 
269 patients), and 4 on NMD (4 data-sets on 149 patients). All included studies 
had a prospective design and major characteristics of study populations are shown 
in Table 8 and Table 9. 
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Table 8. Characteristics of included studies. 
Author Population 
(n) 
Follow-up 
(months) 
Type of surgery Reported outcomes Age 
(years) 
Male gender 
(%) 
Gokce 2005  24 ≥ 3 RYGB FMD 44±10 37 
Lind 2009  19 12 RYGB FMD 41±11 26 
Sturm 2009  37 18 RYGB, LAGB IMT, FMD, NMD 35 (21-52)* NR 
Sarmento 2009  18 12 RYGB IMT 44,1±9,8 0 
Brethauer 2011  15 12 RYGB FMD, NMD 49,2±10,4 36 
Habib (a) 2011  22 6 RYGB IMT, FMD 44,5±2,4 NR 
Habib (b) 2011  28 24 RYGB IMT, FMD 44,8±1,8 NR 
Saleh 2012  47 10 RYGB IMT, FMD, NMD 41 8,5 
Nerla 2012  50 3 RYGB, BPD FMD, NMD 38±9 26 
García 2013  27 12 RYGB, SG IMT 43,5±8,8 22,5 
Tschoner 2013  27 18 RYGB, LAGB IMT, FMD 33,7 (20-51)* 33 
*median value (range) 
RYGB: Roux-en-Y Gastric Bypass; LAGB: laparoscopic adjustable gastric banding; BPD: Biliopancreatic Diversion; SG: Sleeve 
gastrectomy; IMT: Intima-media thickness; FMD: Flow-Mediated Dilation; NMD: Nitrate-Mediated Dilation; NR: Not reported  
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Table 9. Cardiovascular risk factors in included studies. 
Author 
BMI 
(Kg/m
2
) 
Waist 
(cm) 
DM 
(%) 
FPG 
(mg/dl) 
HT 
(%) 
HL 
(%) 
TC 
(mg/dl) 
LDL-c 
(mg/dl) 
HDL-c 
(mg/dl) 
TGs 
(mg/dl) 
Smoking 
(%) 
Gokce  
2005  
50±8 NR 29 119±39 50 50 NR NR NR NR 8 
Lind  
2009 
43,8±3,1 NR NR 117±40 NR NR NR 124±31 43±8 159±62 NR 
Sturm  
2009  
42,4±3,9 113,7±12,7 NR 98,2±11,5 NR NR 194,5±40,8 120,1±34,9 49,4±10,2 120 (58)* 14,2 
Sarmento  
2009  
44,3±6,4 120,2±12,8 16,6 97,9±29,6 47 NR NR 108,5±33,6 51,9±15,7 145,7±72,7 NR 
Brethauer  
2011  
48,7±5,8 132,9±12,5 20 106,7±43,1 73,3 80 200,2±47,7 124,5±38,3 46,4±17,6 146,1±64,5 NR 
Habib (a)  
2011  
47,0±1,0 NR NR NR NR NR 188±6 105±5 49±1 170±13 NR 
Habib (b)  
2011  
47,2±1,4 NR NR NR NR NR 188±8 101±7 52±2 169±16 NR 
Saleh  
2012 
47,1±5,5 129±11,2 NR 94,7±21,7 61,7 23,9 183,4±37,7 113,9±29,2 40,4±9,7 148,6±94,6 4,3 
Nerla  
2012 
47,1±8,4 133±17 8 102±23 34 18 196±35 NR NR 147±30 42 
García  
2013  
38,4±5,0 NR 26 103,1±17,9 68 83 225±50,6 135±35 45±9,3 224±137 26 
Tschoner  
2013  
NR NR NR NR NR NR NR NR NR NR NR 
BMI: body mass index; DM: diabetes mellitus; FPG: fasting plasma glucose; HT: hypertension; HL: hyperlipidemia; TC: Total 
Cholesterol; LDLc: LDL-cholesterol; HDLc: HDL-cholesterol; TGs: triglycerides; NR: not reported. * Median value (interquartile 
range).  
46 
 
 
Six studies 
(130,131,132,133,134,135)
 included obese subjects who had undergone RYGB, 
four studies included patient who had undergone different types of surgery (2 
RYGB and LAGB 
(136,137)
; 1 RYGB and BPD 
(138)
; 1 RYGB and SG 
(139)
. In 6 
studies (7 data-sets) 
(132,133,135,136,137,139)
, obese patients (n=206) showed a 
significant reduction of IMT (MD: -0.17 mm; 95%CI: -0.290, -0.049; P=0.006) 
after bariatric surgery (Figure 10). Heterogeneity among these studies was 
statistically significant (I
2
=99.3%; P<0.00001) and no reduction in the overall 
heterogeneity was found after excluding one study at time. Three studies (4 data-
sets) 
(132,133,135)
, specifically evaluating a total of 115 subjects who had undergone 
RYGB, showed an even more relevant IMT reduction (MD: -0.27 mm; 95%CI: -
0.33, -0.21; P<0.00001) with a significant heterogeneity among studies 
(I
2
=95.5%; P<0.00001). The significant reduction of IMT after bariatric surgery 
was confirmed analyzing only the 4 datasets 
(132,133,135,139)
 with a short-term 
follow-up (≤12 month) with a variation of -0.19 (95%CI: -0.303,-0.085; P=0.001 - 
I
2
=96.4%; P<0.00001). In contrast, the 3 datasets 
(133,136,137)
 considering a long 
term follow-up (>12 month) showed no significant variation in IMT after surgery 
(MD: -0.14 mm; 95%CI: -0.105, 0.387; P=0.263 - I
2
=99.7%; P<0.00001). 
 
Figure 10. Changes in common carotid artery intima-media thickness (c-IMT) 
after bariatric surgery. 
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Eight studies (9 data-sets) 
(130,131,133,135,136,137,138,140)
, evaluating a total of 269 
subjects, showed a significant improvement in FMD after bariatric surgery (MD: 
5.65%; 95%CI: 2.87, 8.03; P<0.001) (Figure 11). A significant heterogeneity 
among studies was found (I
2
=96.5%; P<0.001), which was not reduced by the 
exclusion of one study at time. Five studies (6 data-sets) 
(130,131,133,135,140)
, 
evaluating a total of 155 subjects undergoing RYBG, showed an even more 
relevant FMD improvement (MD: 6.39%; 95%CI: 2.71,10.08; P=0.001) with a 
significant heterogeneity among studies (I
2
=96.1%; P<0.001). Interestingly, 
changes in FMD were confirmed both in the short-term 
(131,133, 135,138,140)
 with a 
variation of 5.02% (95%CI: 1.92, 8.11; P=0.001 - I
2
=94.0%; P<0.001) and in the 
long-term 
(133,136,137)
 with a variation of 6.78% (95%CI: 0.99, 12.57; P=0.022 - 
I
2
=98.6%; P<0.001). 
Four studies (4 data-sets) 
(135,137,138,140) 
evaluating a total of 149 obese subjects, 
showed no significant increase of NMD after bariatric surgery (MD: 2.173%; 
95%CI: -0.796, 5.142; P=0.151) with a significant heterogeneity among studies 
(I
2
=79.4%; P=0.002). After excluding 2 studies evaluating different surgical 
procedures 
(137,138)
, significantly increased NMD values were found after RYGB 
(MD: 4.88%; 95%CI: 2.597,7.170; P<0.00001) without heterogeneity among 
studies (I
2
=0%; P=0.370).  
No significant variation in NMD was found either in the only study 
(137)
 providing 
data on >12 months follow-up (MD: 0.410; 95%CI: -3.248;4.068; P=0.826; I
2
: not 
estimable), or in the 3 datasets 
(135,138,140)
 considering a ≤12 month follow-up (MD: 
2.746; 95%CI: 1.119, 6.690; P=0.172 - I
2
=86.2%; P=0.001). However, after 
excluding the only study with a very short follow-up (3 months) 
(138)
, we found a 
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clear trend toward a significant variation (MD 3.203%; 95%CI: 0.010,6.416; 
P=0.051 ) with a marginally significant heterogeneity (I
2
=59.5%; P=0.085). 
 
Figure 11. Changes in Flow-mediated dilation (Panel A) and Nitrate-mediated 
dilation (Panel B) after bariatric surgery. 
 
Panel A: Flow-mediated dilation (FMD) 
 
Panel B: Nitrate-mediated dilation (NMD) 
 
Regression models showed that age, BMI, waist circumference and basal IMT 
significantly impacted on changes of IMT (Z= -4.55, P<0.001; Z= -3.63, P<0.001; 
- Z= -6.66, P<0.001; Z= -12.72, P<0.001, respectively) while LDLc levels were 
inversely associated with the reduction in IMT values (Z= 4.14, P<0.001). 
Moreover, percentual changes in BMI (Figure 12), body weight, waist 
circumference, SBP and DBP from baseline to post-operative values were 
associated with IMT variation (Z= 11.52, P<0.001; Z= 2.79, P=0.005; Z= 2.28, 
P=0.002; Z= 2.49, P=0.01; Z= 2.51, P=0.01; respectively). In addition, male 
gender, fasting plasma glucose, total cholesterol and LDL-c significantly 
impacted on changes in FMD (Z= -3.04, P=0.002; Z= -2.86, P=0.0; Z= -3.61, 
P<0.001; Z= -3.13, P=0.002, respectively). Percentual changes in BMI (Figure 
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12) and in body weight significantly correlated with FMD improvement (Z= -
4.26, P<0.001; Z= -2.42, P=0.016). Accordingly, fasting plasma glucose, 
percentual changes in BMI (Figure 12), body weight and waist circumference 
significantly correlated with NMD improvement (Z=-2.70, P=0.007; Z=-3.81, 
P<0.001; Z=-3.68, P<0.001; Z=-3.79, P<0.00). Overall, percentual changes in 
IMT values were significantly associated with changes in FMD (Z=-2.55, 
P=0.01). All the other co-variates tested did not impact on IMT, FMD and NMD. 
Figure 12. Meta-regression analysis. Association of Body Mass Index percentual 
changes with modifications in carotid intima-media thickness, flow-mediated 
dilation and nitrate-mediated dilation.  
 
BMI: Body Mass Index; IMT: Intima-media thickness; FMD: Flow-Mediated Dilation; 
NMD: Nitrate-Mediated Dilation; D: percentual changes from baseline values to post-
operative values  
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The results of the present meta-analysis on 314 obese patients show that bariatric 
surgery is associated with a significant improvement of structural and functional 
markers of atherosclerosis. In detail, subjects undergoing bariatric surgery showed 
a significant reduction of carotid IMT (-0.17 mm), accompanied by a 5.6% 
increase in FMD. In line with these findings, NMD showed a tendency toward 
improvement after bariatric surgery, reaching the statistical significance only in 
studies evaluating RYGB.  
Meta-regression analyses showed that the older age, the higher body weight and 
waist circumference, the higher the IMT. In contrast, the lower the LDL-c levels 
at baseline the larger was the reduction of IMT after bariatric surgery. Moreover, 
whereas the male gender, fasting plasma glucose levels, total cholesterol and 
LDL-c predicted higher changes in FMD, variations in NMD were predicted only 
by fasting plasma glucose levels. As a further confirmation, we also found that 
changes in weight, BMI, waist circumference, systolic and diastolic blood 
pressure significantly and positively predicted the modifications of IMT. 
Interestingly, changes in body weight, BMI and waist circumference resulted 
associated with changes in FMD and/or NMD.  
Overall, our data suggest a consistent cardioprotective effect of bariatric surgery 
through its beneficial effects on subclinical atherosclerosis and on endothelial 
function. 
Several mechanisms may be involved in the improvement of these parameters 
after bariatric surgery. In detail, bariatric surgery is effective in reducing the main 
cardiovascular risk factors such as insulin resistance, type 2 diabetes, 
hypertension, hyperlipidemia and that the magnitude of this reduction exceeds the 
effect of weight loss itself 
(51,141)
. Moreover, bariatric surgery exerts an important 
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modulation on the haemostatic and fibrinolytic balance being able to reduce the 
hypercoagulable state typical of obese subjects 
(107)
. It is important to highlight 
that many of these effects of bariatric surgery are observed within the first 12 
month of the postoperative period. Accordingly, we demonstrated that the 
improvement of IMT and FMD is relevant at the short term follow-up (≤12 
months), while it becomes less evident thereafter. 
In conclusion, in our meta-analysis bariatric surgery is associated with an 
improvement of subclinical atherosclerosis and endothelial function. These effects 
may significantly contribute to the reduction of cardiovascular risk in patients 
who undergo bariatric operations. This evidence further supports the use of 
bariatric surgery as a lifesaving therapy with a goal of reducing cardiovascular 
morbidity/mortality, especially in patients with a high obesity-related 
cardiovascular risk.  
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4.2 Bariatric surgery and nutritional issues 
Beside surgical complications, one of the major concerns of bariatric surgery is 
the worsening of nutritional status. Indeed, nutritional deficiencies are well-
recognized complications after different bariatric procedures. 
Several studies have assessed the nutritional status after bariatric surgery, 
reporting multiple deficiencies especially after malabsorptive procedures, such as 
RYGB and BPD. Of note, these nutritional complications have been described 
also after restrictive interventions such as SG and AGB. 
There are several reports on micronutrient deficiencies, (i.e., vitamins A, D, B1, 
B6, folic acid) and minerals (calcium, iron, zinc, copper and magnesium). 
Macronutrient deficiencies or clinical events related to frank malnutrition (total 
energy intake less than 50% the nutritional needs 
(142,143)
 are less frequent 
(144)
. 
Osteomalacia/osteoporosis and anemia are the most widely reported adverse 
clinical outcomes 
(145,146)
. Protein malnutrition and anemia, among others, could 
be attributed to 1) reduced food intake (vomiting, food aversion, modified eating 
behavior and nonadherence to dietary recommendations), 2) reduced gastric acid 
secretion, and/or malabsorption following the exclusion of sites of absorption of 
various minerals and vitamins (duodenum and proximal jejunum) 
(142)
.  
A growing literature now attests the occurrence of nutrient deficiencies in 
morbidly obese individuals prior to bariatric surgery, which may be aggravated by 
surgical procedures, resulting in more serious postoperative complications. Thus, 
we performed a systematic review and meta-analysis to evaluate the prevalence of 
nutrient deficiencies in obese patients before bariatric surgery.  
A total of 29 articles (32 datasets) were included in the analysis. The major 
characteristics of the included studies are shown in Table 10. 
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Table 10. Major characteristics of included studies. 
Author Design Procedure Reported outcomes 
Ben-porat 2015 
(147)
 Retrospective SG Hb, Iron, Ferritin, Folate, Vit B12, Vit D 
Blume 2012 
(148)
 Retrospective RYGB Albumin, Hb, Iron, Ferritin, Folate, Vit B12 
Carrodeguas 2005 
(149)
 
Retrospective 
AGB, 
RYGB 
Vit B1 
Censani 2013
 (150)
 NR Restrictive Vit D 
Dagan 2016 
(151)
 NR SG 
Hb, Iron, Ferritin, Folate, Vit B1, Vit B12, 
Vit D 
Damms-Machado 
2012
 (152)
 
NR SG 
Ca, K, Iron, Folate, Vit B1, Vit B6, Vit 
B12, Vit A, Vit E, Vit D 
de Luis 2013 
(153)
 NR BPD 
Albumin, Cu, Zn, Ca, P, Hb, Ferritin, 
Folate, Vit B12, Vit A, Vit E, Vit K, Vit D 
Ernst 2009
 (154)
 NR NR 
Albumin, Zn, Mg, P, Hb, Ferritin, Folate, 
Vit B12, Vit D 
Ewang-Emukowhate  
2015 
(155)
 
Prospective NR Iron, Folate, Vit B12, Vit K, Vit D 
Flancbaum 2006 
(156)
 Retrospective RYGB 
Albumin, Ca, Hb, Iron, Ferritin, Vit B1, Vit 
B12, Vit D 
Gehrer 2010 
(157)
 Prospective SG, RYGB 
Albumin, Zn, Ca, Iron, Folate, Vit B1, Vit 
B6, Vit B12, Vit D 
Gemmel 2009 
(158)
 Retrospective 
AGB, SG, 
RYGB, BPD 
Folate, Vit B12, Vit A, Vit D 
Gerig 2013 
(159)
 Retrospective NR 
Cu, Zn, Mg, Ca, P, Hb, Ferritin, Folate, Vit 
B12, Vit D 
Gillon 2016 
(160)
 NR SG Hb, Ferritin, Folate, Vit B12, Vit D 
Gobato 2014 
(161)
 Prospective RYGB Cu, Zn, Mg, Iron, Ferritin, Folate 
Jin 2009 
(162)
 Retrospective RYGB Vit D 
Lefebvre 2014 
(163)
 Crossectional NR 
Zn, Se, Mg, Ca, P, Hb, Iron, Ferritin, Vit 
B12, Vit A, Vit D 
Madan 2006 
(164)
 Retrospective RYGB 
Zn, Se, Iron, Ferritin, Folate, Vit B12, Vit 
A, Vit D 
Moize 2011 
(165)
 Retrospective NR 
Albumin, Zn, Mg, Ca, Hb, Iron, Ferritin, 
Folate, Vit B1, Vit B6, Vit B12, Vit D 
Papamargaritis  
2015 
(166)
 
Retrospective 
AGB, SG, 
RYBG 
Cu, Zn, Se 
Peterson 2016 
(167)
 Prospective RYGB 
Iron, Folate, Vit B1, Vit B12, Vit A, Vit E, 
Vit D 
Sanchez 2016 
(168)
 NR SG, RYGB 
Albumin, Cu, Zn Ca, P, Hb, Iron, Ferritin, 
Folate, Vit B12, Vit D 
Schiavo 2016 
(169)
 Prospective NR 
Zn, Se, Mg, Iron, Folate, Vit B12, Vit A, 
Vit C, Vit E, Vit D 
Schweiger 2010 
(170)
 NR 
AGB, SG, 
RYGB, BPD 
Albumin, Ca, P, Hb, Iron, Ferritin, Folate, 
Vit B12 
Skroubis 2002 
(171)
 Retrospective RYGB, BPD Hb, Iron, Ferritin, Vit B12 
Toh 2009 
(172)
 Retrospective 
AGB, SG, 
RYGB 
Albumin, Hb, Iron, Ferritin, Folate, Vit 
B12, Vit D 
van Rutte 2014 
(173)
 Retrospective SG 
Albumin, Zn, Mg, Ca, P, Hb, Iron, Ferritin, 
Folate, Vit B1, Vit B6, Vit B12, Vit A, Vit 
D 
Wang 2016 
(174)
 Retrospective NR 
Albumin, Mg, Ca, P, K, Iron, Ferritin, 
Folate, Vit B12, Vit D 
Wolf 2015 
(175)
 NR SG Albumin, Mg, Ca, P, Vit A, Vit C, Vit D 
RYGB: Roux-en-Y Gastric Bypass; AGB: adjustable gastric banding; BPD: Biliopancreatic Diversion; 
SG: Sleeve gastrectomy; NR: not reported; Ca: calcium; Cu: copper; Hb: hemoglobin; K: potassium; Mg: 
magnesium; P: phosphate; Se: selenium; Vit: vitamin; Zn: zinc. 
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Fourteen studies had a retrospective design, six were prospective while for the 
remainders the design was not clearly reported. Moreover, a range of 
micronutrient and vitamin deficiencies were assessed in the different studies. 
The outcomes included: albumin, copper, zinc, magnesium, potassium, calcium, 
phosphate, hemoglobin, iron, ferritin, folate, vitamin B1, B6, B12, A, C, E, K, 25 
(OH) vitamin D. As reported in Table 11, 25 (OH) vitamin D deficiency (i.e. 25 
(OH) vitamin D < 20 ng/dl) was the most frequent deficit in the studies analyzed 
(59.8%, 95%CI: 51.1-67.9) with a prevalence of severe deficiency (i.e. 25 (OH) 
vitamin D < 10 ng/dl) of 19.2% (95%CI: 14.4-25.1). Similarly, we found a high 
prevalence of deficit of vitamin C, iron and zinc (23.4%, 21.7% and 14.8%, 
respectively). 
Table 11. Weighted mean prevalence (WMP) of micronutrient and vitamin 
deficiencies in obese patients before bariatric surgery.  
Outcome Datasets 
(n) 
Subjects 
(n) 
WMP 
(%) 
95%CI I
2
 P 
Albumin 12 2288 4 1.6-9.8 93.3 < 0.001 
Hemoglobin 19 4046 8.6 6.2-11.8 89.9 < 0.001 
Iron 20 2564 21.7 16.0-28.7 92.7 < 0.001 
Ferritin 20 3778 6.2 4.6-8.3 77.2 < 0.001 
Folate 21 3178 7.6 4.8-11.8 91.8 < 0.001 
Vitamin B1 7 1105 8.4 4.1-16.6 91.2 < 0.001 
Vitamin B6 4 429 5.4 1.6-16.9 81.7 0.001 
Vitamin B12 24 4045 7.4 5.2-10.3 88.7 < 0.001 
       
Vitamin A 9 1096 6.5 3.6-11.4 73.2 < 0.001 
Vitamin C 2 83 23.4 10.3-44.9 70.2 0.067 
Vitamin D <30 ng/dl 12 1597 87.8 72.9-95.1 97.2 < 0.001 
Vitamin D <20 ng/dl 17 2248 59.8 51.1-67.9 93.0 < 0.001 
Vitamin D <10 ng/dl 7 1354 19.2 14.4-25.1 82.2 < 0.001 
Vitamin E 4 267 2.1 0.6-6.8 24 0.267 
Vitamin K 2 233 6.1 0-89.9 91.9 < 0.001 
       
Zinc 12 1623 14.8 7.4-27.5 95.1 < 0.001 
Copper 5 702 4.7 0.4-39.8 97.7 < 0.001 
Magnesium 9 1574 4 1.4-10.6 94.7 < 0.001 
Potassium 2 241 5.8 3.5-9.6 0 0.830 
Selenium 4 365 11.2 1.5-50.3 95.9 < 0.001 
Calcium 12 2160 2.2 1.0-4.8 84.7 < 0.001 
Phosphate 9 1615 7.6 4.6-12.3 85.3 < 0.001 
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Although nutritional deficiencies in obesity are multifactorial, low quality diet 
may greatly contribute to these events. Indeed, high intake of high caloric density 
foods with low nutritional quality may not be able to meet the individual 
micronutrient needs. In addition, other mechanisms may be involved, such as 
defective storage and bioavailability of some nutrients (e.g., vitamin D), increased 
hepcidin synthesis leading to reduced iron absorption due to chronic 
inflammation, and overgrowth of small intestinal bacterial, which may consume 
vitamin B1 and B12 and fat soluble vitamins leading to their shortage 
(176)
.  
Vitamin D deficiency deserves a particular comment. Beside its consequences on 
several body organ systems 
(177,178,179)
, vitamin D deficiency can cause unbalanced 
resorptive bone loss leading to osteopenia and osteoporosis. This is particularly 
important in the bariatric population because these patients are at risk for 
fractures, being predominantly females and perimenopausal. Vitamin D 
insufficiency is a common issue in obese individuals as well as in bariatric 
patients 
(180)
, and obesity per se represents a risk factor for vitamin D deficiency 
and often requires substantial supplementation to achieve sufficiency 
(181)
. It has 
been hypothesized that obese individuals are more likely to be deficient in vitamin 
D because of the higher volumetric dilution and sequestration of this fat-soluble 
hormone in the adipose tissue 
(182)
. As fat mass increases, an individual will 
require greater amounts of vitamin D (via photoproduction from sun exposure, 
dietary intake, and/or supplementation). Moreover, although there is no difference 
in vitamin D3 production between obese and lean individuals, obese patients may 
have impaired release of vitamin D3 from the skin 
(183)
. Genetic variation in the 
function of the vitamin D binding protein and vitamin D receptor may also 
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influence 25(OH)D levels, with some studies suggesting higher frequency of the 
poorer functioning forms in obesity 
(184,185)
. 
Interestingly, in our study we found a high heterogeneity among studies in most of 
the evaluated outcomes (Table 11). This could be due to differences in study 
design and number of studies. Accordingly, we performed some sensitivity 
analyses including only studies with a prospective design (Table 12). This 
sensitivity analysis confirmed that the most frequent deficiencies involved 
25(OH)vitamin D, iron and zinc. 
It is noteworthy that the number of studies reporting the analyzed outcomes was 
highly variable, ranging from 21 to 2 studies (Figure 13). In particular, for 
Vitamin B6, Vitamin C, Vitamin E, Vitamin K, Copper, Potassium and Selenium 
≤ 5 studies are available. This should be taken into account when interpreting the 
present results and could suggest that, for some micronutrients and vitamins, 
further prospective studies are needed to definitely estimate the prevalence of 
deficiency in obese subjects before bariatric surgery. 
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Table 12. Sensitivity analysis including studies with a prospective design. 
Outcome Datasets 
(n) 
Subjects 
(n) 
WMP 
(%) 
95%CI I
2
 P 
Albumin 0 - - - - - 
Hemoglobin 1 - - - - - 
Iron 6 614 20.2 9.8-37.2 92.5 <0.001 
Ferritin 2 263 5.4 3.2-9.0 0 0.474 
Folate 5 388 7.6 3.1-17.2 77.5 0.001 
Vitamin B1 2 194 1.0 0.2-4.9 0 0.368 
Vitamin B6 1 - - - - - 
Vitamin B12 5* 579 8.3 3.4-18.6 88.1 <0.001 
       
Vitamin A 3** 317 9.6 3.6-23.3 69.8 0.037 
Vitamin C 1 - - - - - 
Vitamin D <30 ng/dl 3 216 86.3 63.2-95.8 88.8 <0.001 
Vitamin D <20 ng/dl 3 418 53.3 22.8-81.5 97.1 <0.001 
Vitamin D <10 ng/dl 2 342 24.6 20.3-29.4 0 0.795 
Vitamin E 2 98 4.2 1.5-11.3 0 0.335 
Vitamin K 1 - - - - - 
       
Zinc 4 434 12.7 3.2-39.4 92.6 <0.001 
Copper 1 - - - - - 
Magnesium 3 296 6.8 0.5-51 86.8 0.001 
Potassium 0 - - - - - 
Selenium 2 262 7.0 1.4-28.1 87.9 0.004 
Calcium 2 399 1.1 0.4-3.1 0 0.397 
Phosphate 1 - - - - - 
*After exclusion of the study by Ewang et al that included patients receiving nutrients 
supplementation and used a cut-off to define Vitamin B12 deficiency different from the 
other we obtain a WMP: 6.1% (95% CI: 3.4-10.7) I
2
: 45.3%, p=0.140 
** After exclusion of the study by Lefebvre et al that used a cut-off to define Vitamin A 
deficiency different from the other we obtain a WMP: 5.1%(95%CI: 0.9-24) I
2
61.9%, 
p=0.105 
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Figure 13. Weighted mean prevalence of micronutrient and vitamin deficiencies 
in obese patients before bariatric surgery.  
 
The size of each circle is proportional to the number of datasets for each outcome. 
Ca: calcium; Cu: copper; Hb: hemoglobin; K: potassium; Mg: magnesium; P: 
phosphate; Se: selenium; Vit: vitamin; Zn: zinc. 
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5. Conclusions 
Extensive evidence supports the efficacy of bariatric surgery in reducing body 
weight and obesity-related comorbidities in severely obese patients. In our studies, 
we found a significant improvement of glucose and lipid homeostasis in obese 
T2DM patients 1-2 years after bariatric surgery. The rate of diabetes remission at 
1 year was 76% after SG and 86% after RYGB and the two major determinants of 
glucose homeostasis, i.e. beta cell function and insulin sensitivity, improved to a 
similar extent after either procedures. These results were achieved in the face of a 
different pattern of GI hormone profile, suggesting that weight loss and the 
consequent improvement of insulin sensitivity are the main determinants of 
diabetes remission, at least several months after surgery. Interestingly, while 
plasma triglycerides decreased to a similar extent with the two procedures, total 
and LDL-cholesterol decreased more consistently after RYGB than SG; 
furthermore, the decrease in LDL-cholesterol was inversely related to meal-
induced GLP-1 response suggesting that GLP-1 restoration is crucial for the 
improvement of cholesterol metabolism, possibly through an increase in 
circulating bile acids.  
The overall metabolic improvement induced by bariatric surgery translates into 
clear benefits in terms of cardiovascular risk. Indeed, we have documented a 
reduction in carotid intima-media thickness and an increase in endothelial 
function after bariatric procedures. These changes in markers of subclinical 
atherosclerosis are in line with the reduction in cardiovascular morbidity and 
mortality, consistently shown by large population studies. Thus, the 
cardioprotective effects of bariatric surgery range from improvement in early 
signs of subclinical atherosclerosis to prevention of major fatal and non-fatal 
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cardiovascular and cerebrovascular events. Further extending this finding, we 
have documented that bariatric surgery is able to improve the obesity-related 
hypercoagulable state characterized by increased levels of clotting factors and 
impaired fibrinolysis. However, it is important to note that at 2-month post-
operative follow-up, we observed a significant decrease in natural anticoagulants, 
probably due to reduction of vitamin K absorption. This decrease could 
potentially lead to increased thrombotic risk. Since our data have been obtained in 
the early post-operative phase, no definite conclusion on the long-term effect of 
bariatric surgery on coagulant/anticoagulant balance can be drawn.  
Despite the proven efficacy of bariatric surgery in improving overall metabolic 
control and reducing total and cardiovascular mortality, some concerns can be 
raised regarding two main points: 1) increased glucose variability and 2) 
alterations of nutritional status. 
With regard to the former, we have found that some patients classified as diabetes 
remitters according to currently validated criteria, suffer from high glycemic 
variability, i.e., they present ample glucose excursions throughout the day, often 
reaching frank hypoglycemic threshold. This alteration is likely to be 
underdiagnosed since it can be detected only by continuous glucose monitoring. 
Even more interesting is the observation that high GV is associated with increased 
oxidative stress, indicating an increased risk of vascular damage. Based on these 
findings, we propose that GV be included among criteria for the definition of 
diabetes remission in order to have a comprehensive picture of the impact of 
bariatric surgery on glucose homeostasis. Furthermore, since high GV is likely 
involved in the pathogenesis of vascular complications and mortality risk, at least 
in diabetic patients, ad hoc studies should be performed to identify and to manage 
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appropriately glycemic variability. Of great interest is the possibility to reduce GV 
by proper nutritional measures, such as low-glycemic index food.  
The latter issue is one that involves nutrient deficiencies. Several studies have 
consistently documented a high prevalence of vitamin and mineral deficiencies 
after bariatric procedures. Poor postoperative nutrient intake, recurrent vomiting, 
inadequate supplementation are important risk factors. In addition, reviewing the 
available literature, we have documented that a considerable number of obese 
patients present vitamin and/or micronutrient deficiencies already before surgery, 
vitamin D deficit being the most frequent abnormality (about 60%). The high 
prevalence of pre-operative nutritional deficiency underlines the need of a careful 
nutritional screening in all patients scheduled for bariatric surgery in order to 
detect and correct any possible deficiency before intervention. Likewise, effective 
strategies should be implemented to improve long-term patients’ adherence to 
lifestyle and nutritional recommendations in order to maximize the benefits of 
bariatric surgery and reducing the risk of the above discussed complications.  
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